Dexcom Inc Stock Price To Earnings To Growth

DXCM Stock

USD 124.34 13.67 9.91%

DexCom Inc fundamentals help investors to digest information that contributes to DexCom's financial success or failures. It also enables traders to predict the movement of DexCom Stock. The fundamental analysis module provides a way to measure DexCom's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DexCom stock.

Other Current Liab Total Current Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

DexCom Inc Company Price To Earnings To Growth Analysis

DexCom's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Current DexCom Price To Earnings To Growth

2.53 X

Most of DexCom's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

DexCom Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for DexCom is extremely important. It helps to project a fair market value of DexCom Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since DexCom's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DexCom's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DexCom's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Total Current Assets	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Property Plant Equipment	Short Term Investments	Long Term Debt	Net Receivables	Short Term Debt	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Good Will	Capital Surpluse	Treasury Stock	Intangible Assets	Long Term Debt Total	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.95	1.0	0.81	0.75	0.99	0.81	0.98	0.98	0.97	0.97	0.4	0.76	1.0	0.81	0.84	0.88	-0.92	0.87	0.85	0.91	0.86	0.96	0.92	0.8
Total Stockholder Equity	0.98		0.89	0.98	0.73	0.8	0.96	0.72	0.94	0.97	0.93	0.92	0.42	0.65	0.99	0.8	0.87	0.92	-0.93	0.81	0.89	0.89	0.81	0.98	0.94	0.7
Net Debt	0.95	0.89		0.93	0.9	0.63	0.97	0.89	0.96	0.96	0.91	0.97	0.37	0.86	0.94	0.68	0.67	0.74	-0.83	0.89	0.7	0.79	0.81	0.88	0.81	0.89
Total Current Assets	1.0	0.98	0.93		0.76	0.73	0.99	0.77	0.95	0.98	0.98	0.96	0.36	0.73	0.99	0.83	0.86	0.9	-0.92	0.83	0.89	0.93	0.87	0.96	0.94	0.75
Retained Earnings	0.81	0.73	0.9	0.76		0.51	0.84	0.88	0.88	0.79	0.75	0.88	0.35	0.94	0.8	0.42	0.42	0.52	-0.69	0.87	0.44	0.54	0.65	0.74	0.62	0.92
Accounts Payable	0.75	0.8	0.63	0.73	0.51		0.7	0.58	0.75	0.71	0.58	0.67	0.81	0.41	0.75	0.61	0.8	0.77	-0.83	0.78	0.7	0.68	0.54	0.8	0.63	0.55
Total Liab	0.99	0.96	0.97	0.99	0.84	0.7		0.85	0.98	0.97	0.97	0.99	0.37	0.82	0.98	0.8	0.8	0.85	-0.91	0.89	0.82	0.9	0.88	0.94	0.89	0.84
Common Stock	0.81	0.72	0.89	0.77	0.88	0.58	0.85		0.89	0.76	0.75	0.91	0.47	0.91	0.78	0.57	0.54	0.56	-0.71	0.95	0.43	0.63	0.71	0.71	0.55	0.99
Property Plant Equipment	0.98	0.94	0.96	0.95	0.88	0.75	0.98	0.89		0.94	0.92	0.99	0.44	0.84	0.97	0.74	0.77	0.81	-0.9	0.93	0.74	0.82	0.82	0.92	0.83	0.88
Short Term Investments	0.98	0.97	0.96	0.98	0.79	0.71	0.97	0.76	0.94		0.95	0.94	0.37	0.71	0.98	0.76	0.8	0.87	-0.89	0.81	0.86	0.88	0.83	0.96	0.93	0.74
Long Term Debt	0.97	0.93	0.91	0.98	0.75	0.58	0.97	0.75	0.92	0.95		0.95	0.17	0.75	0.96	0.83	0.8	0.85	-0.87	0.76	0.86	0.93	0.9	0.91	0.93	0.73
Net Receivables	0.97	0.92	0.97	0.96	0.88	0.67	0.99	0.91	0.99	0.94	0.95		0.36	0.87	0.96	0.77	0.75	0.79	-0.87	0.91	0.73	0.85	0.86	0.9	0.83	0.9
Short Term Debt	0.4	0.42	0.37	0.36	0.35	0.81	0.37	0.47	0.44	0.37	0.17	0.36		0.27	0.38	0.23	0.41	0.38	-0.48	0.66	0.29	0.3	0.19	0.46	0.19	0.47
Current Deferred Revenue	0.76	0.65	0.86	0.73	0.94	0.41	0.82	0.91	0.84	0.71	0.75	0.87	0.27		0.74	0.52	0.42	0.47	-0.63	0.86	0.38	0.59	0.71	0.64	0.53	0.95
Net Tangible Assets	1.0	0.99	0.94	0.99	0.8	0.75	0.98	0.78	0.97	0.98	0.96	0.96	0.38	0.74		0.79	0.83	0.89	-0.92	0.84	0.86	0.88	0.84	0.97	0.93	0.77
Total Permanent Equity	0.81	0.8	0.68	0.83	0.42	0.61	0.8	0.57	0.74	0.76	0.83	0.77	0.23	0.52	0.79		0.9	0.84	-0.75	0.62	0.82	0.91	0.83	0.75	0.76	0.52
Good Will	0.84	0.87	0.67	0.86	0.42	0.8	0.8	0.54	0.77	0.8	0.8	0.75	0.41	0.42	0.83	0.9		0.97	-0.85	0.65	0.92	0.9	0.84	0.88	0.85	0.48
Capital Surpluse	0.88	0.92	0.74	0.9	0.52	0.77	0.85	0.56	0.81	0.87	0.85	0.79	0.38	0.47	0.89	0.84	0.97		-0.88	0.67	0.96	0.9	0.88	0.94	0.93	0.51
Treasury Stock	-0.92	-0.93	-0.83	-0.92	-0.69	-0.83	-0.91	-0.71	-0.9	-0.89	-0.87	-0.87	-0.48	-0.63	-0.92	-0.75	-0.85	-0.88		-0.81	-0.85	-0.87	-0.79	-0.93	-0.87	-0.68
Intangible Assets	0.87	0.81	0.89	0.83	0.87	0.78	0.89	0.95	0.93	0.81	0.76	0.91	0.66	0.86	0.84	0.62	0.65	0.67	-0.81		0.56	0.7	0.72	0.81	0.62	0.95
Long Term Debt Total	0.85	0.89	0.7	0.89	0.44	0.7	0.82	0.43	0.74	0.86	0.86	0.73	0.29	0.38	0.86	0.82	0.92	0.96	-0.85	0.56		0.92	0.82	0.91	0.95	0.4
Short Long Term Debt	0.91	0.89	0.79	0.93	0.54	0.68	0.9	0.63	0.82	0.88	0.93	0.85	0.3	0.59	0.88	0.91	0.9	0.9	-0.87	0.7	0.92		0.89	0.87	0.89	0.59
Long Term Investments	0.86	0.81	0.81	0.87	0.65	0.54	0.88	0.71	0.82	0.83	0.9	0.86	0.19	0.71	0.84	0.83	0.84	0.88	-0.79	0.72	0.82	0.89		0.85	0.84	0.69
Net Invested Capital	0.96	0.98	0.88	0.96	0.74	0.8	0.94	0.71	0.92	0.96	0.91	0.9	0.46	0.64	0.97	0.75	0.88	0.94	-0.93	0.81	0.91	0.87	0.85		0.95	0.69
Net Working Capital	0.92	0.94	0.81	0.94	0.62	0.63	0.89	0.55	0.83	0.93	0.93	0.83	0.19	0.53	0.93	0.76	0.85	0.93	-0.87	0.62	0.95	0.89	0.84	0.95		0.52
Capital Stock	0.8	0.7	0.89	0.75	0.92	0.55	0.84	0.99	0.88	0.74	0.73	0.9	0.47	0.95	0.77	0.52	0.48	0.51	-0.68	0.95	0.4	0.59	0.69	0.69	0.52

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict DexCom

DexCom Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

1.57

At this time, DexCom's Price Earnings To Growth Ratio is very stable compared to the past year.

Based on the latest financial disclosure, DexCom Inc has a Price To Earnings To Growth of 2.5317 times. This is 256.58% higher than that of the Health Care Equipment & Supplies sector and 33.25% higher than that of the Health Care industry. The price to earnings to growth for all United States stocks is 48.23% higher than that of the company.

DexCom Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.

DexCom is currently under evaluation in price to earnings to growth category among related companies.

DexCom ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DexCom's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DexCom's managers, analysts, and investors.

Environment Score

Governance Score

Social Score

DexCom Fundamentals

	Return On Equity	0.29
	Return On Asset	0.0679
	Profit Margin	0.17 %
	Operating Margin	0.11 %
	Current Valuation	54.52 B
	Shares Outstanding	396.03 M
	Shares Owned By Insiders	0.35 %
	Shares Owned By Institutions	99.64 %
	Number Of Shares Shorted	11.77 M
	Price To Earning	245.31 X
	Price To Book	25.38 X
	Price To Sales	14.49 X
	Revenue	3.62 B
	Gross Profit	1.88 B
	EBITDA	916.7 M
	Net Income	541.5 M
	Cash And Equivalents	2.37 B
	Cash Per Share	6.14 X
	Total Debt	2.59 B
	Debt To Equity	1.17 %
	Current Ratio	3.77 X
	Book Value Per Share	5.67 X
	Cash Flow From Operations	748.5 M
	Short Ratio	4.81 X
	Earnings Per Share	1.30 X
	Price To Earnings To Growth	2.53 X
	Target Price	151.32
	Number Of Employees	9.5 K
	Beta	1.21
	Market Capitalization	49.24 B
	Total Asset	6.26 B
	Retained Earnings	1.02 B
	Working Capital	2.87 B
	Current Asset	231.3 M
	Current Liabilities	66.9 M
	Net Asset	6.26 B

About DexCom Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with DexCom

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.

Moving against DexCom Stock

0.75	DNA	Ginkgo Bioworks Holdings Financial Report 8th of May 2024	Pair Corr
0.61	IDXX	IDEXX Laboratories Financial Report 7th of May 2024	Pair Corr
0.6	GH	Guardant Health Financial Report 14th of May 2024	Pair Corr
0.45	CTSO	Cytosorbents Crp Financial Report 7th of May 2024	Pair Corr
0.43	GMED	Globus Medical Financial Report 2nd of May 2024	Pair Corr

The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.

The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:

How To Invest In DexCom

Details

Is DexCom Stock a good investment?

Details

What is DexCom's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out DexCom Piotroski F Score and DexCom Altman Z Score analysis.

Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for DexCom Stock analysis

When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.

	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	CEOs Directory Screen CEOs from public companies around the world
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope

Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

2.001

Earnings Share

1.3

Revenue Per Share

9.827

Quarterly Revenue Growth

0.242

Return On Assets

0.0679

The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dexcom Inc Stock Price To Earnings To Growth

DexCom Inc Company Price To Earnings To Growth Analysis

PEG Ratio

PE Ratio

EPS Growth

Current DexCom Price To Earnings To Growth

DexCom Price To Earnings To Growth Driver Correlations

DexCom Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

1.57

DexCom Price To Earnings To Growth Peer Comparison

DexCom ESG Sustainability

DexCom Fundamentals

About DexCom Fundamental Analysis

Pair Trading with DexCom

Moving against DexCom Stock

Complementary Tools for DexCom Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY